Dear COVID-19 Vaccination Provider:

On September 24, 2021, under the U.S. Food and Drug Administration’s (FDA) updated emergency use authorization (EUA), the CDC issued recommendations for a single dose of the Pfizer-BioNTech COVID-19 Vaccine at least six months after completion of the primary series for the following individuals:

•             individuals 65 years of age and older, and residents in long-term care settings

•             individuals 50-64 years of age with underlying medical conditions

•             individuals 18-49 years of age with underlying medical conditions, based on individual benefit and risks.
             (This can be based on shared clinical decision-making and encourages, but does not require, prior consultation with a provider before administration of a booster dose.)

•             individuals 18-64 years of age who are at increased risk for COVID-19 exposure and transmission because of occupational or institutional setting, based on their individual benefits and risks. 

Due to insufficient data at this time, the EUA amendment for a booster dose does not apply to the Moderna COVID-19 vaccine or the Janssen/Johnson & Johnson COVID-19 vaccine, and does not support the use of a Pfizer-BioNTech COVID-19 vaccine dose after two doses of the Moderna COVID-19 vaccination or the single-dose Janssen/Johnson & Johnson COVID-19 vaccination. 

All providers enrolled in the NYS COVID-19 vaccination program are authorized to expand eligibility for these individuals to receive booster doses, effective immediately. 

Please see the attached program guidance for important operational details including specific eligibility.

Screening Checklist for the COVID-19 Vaccine

Thank you for your participation in the COVID-19 Vaccination Program. 

The NYS COVID-19 Vaccine Team